Creative Touch Permanent Makeup and Aesthetics

Omega-3 fatty acids matter for skin through a mechanism that is more precise than “anti-inflammatory” implies. EPA and DHA compete directly with arachidonic acid (AA) for incorporation into membrane phospholipids. Because the inflammatory eicosanoids that drive skin conditions including AD, psoriasis, and acne are synthesised from AA, increasing the EPA:AA ratio in keratinocyte and immune cell membranes shifts the entire downstream eicosanoid profile. EPA is more effective than DHA at this epidermal AA displacement, producing PGE₃ and resolvins rather than the PGE₂ and LTB₄ that sustain inflammatory skin disease. A 2023 Mendelian randomisation study confirmed a causal, not merely associative, relationship between higher n-3 fatty acid levels and reduced AD risk, operating through the FADS gene cluster that governs fatty acid synthesis. This is not a general wellness claim; it is a specific mechanism with primary evidence.

Omega-3 fatty acids are a family of polyunsaturated fats defined by a double bond at the third carbon from the methyl end of the chain. Three forms matter in human nutrition. Alpha-linolenic acid (ALA) is the plant-source form found in flaxseed, walnuts, chia and is technically essential, meaning the body cannot make it. But it converts to the active forms at disappointingly low rates: roughly 5–10% becomes EPA, and under 1% reaches DHA. The work is done by EPA and DHA, not ALA itself. EPA (eicosapentaenoic acid) is the eicosanoid-competing form; the one that changes what inflammatory signals your cells are producing. DHA (docosahexaenoic acid) is more structural, embedding into cell membranes and influencing their fluidity and receptor function. Both come primarily from oily fish and marine algae. ^[2]

Why Omega-3s Actually Work: The Arachidonic Acid Story

Here is what is actually happening when omega-3 fatty acids reduce inflammation, and it is worth understanding precisely, because it explains both why the effect is real and why it requires consistent dietary intake rather than a short course.

Arachidonic acid (AA) is an omega-6 fatty acid that sits in your cell membranes, waiting. When inflammation is triggered, it is released and converted by two enzymes – cyclooxygenase (COX) and lipoxygenase (LOX) – into prostaglandin E₂ (PGE₂) and leukotriene B₄ (LTB₄). These are the primary pro-inflammatory lipid mediators in skin: they drive vasodilation, mast cell activation, keratinocyte proliferation, and immune cell recruitment. They are also, notably, what ibuprofen and corticosteroids target. ^[3]

EPA does not block this pathway. It competes with it. EPA incorporates into the same membrane phospholipid positions that AA occupies, which means COX and LOX have EPA available as an alternative substrate alongside AA. When COX acts on EPA instead of AA, it produces PGE₃ rather than PGE₂. LOX acting on EPA produces LTB₅ rather than LTB₄. Both are significantly less pro-inflammatory and may actively block the AA-derived versions from binding their receptors. The result is not suppressed inflammation but a quieter, less amplified version of it. ^[3]

EPA and DHA go further still. They serve as precursors for resolvins, a class of lipid mediators that actively terminate inflammation rather than simply failing to amplify it. EPA produces E-series resolvins; DHA produces D-series resolvins and protectins. These are not passive molecules. They send a “stand down” signal to the inflammatory cascade. And they are entirely absent from the omega-6 pathway; you only get them if EPA and DHA are present. ^[3]

EPA and DHA Are Not the Same Thing

This distinction gets lost in most supplement marketing, which treats EPA and DHA as interchangeable. They are not, at least not for skin.

A 2019 study using mass spectrometry-based lipidomics gave healthy volunteers either EPA or DHA alone for ten weeks and measured what happened in their skin. EPA was significantly more effective at displacing AA-derived mediators in the epidermis specifically – elevating PGE₃, 12-HEPE, and EPEA in epidermal phospholipids, a measurable shift toward homeostatic rather than inflammatory signalling. DHA’s role is more membrane-structural: it maintains fluidity and receptor mobility rather than competing for the eicosanoid pathway. ^[4]

This matters practically. A fish oil supplement with combined EPA and DHA is well-suited for skin inflammation. A supplement providing DHA alone, which some algae-derived products do, provides less of the eicosanoid-competitive benefit. Worth checking the label.

The Ratio Conversation: Mechanism Over Marketing

The omega-6/omega-3 ratio is everywhere in wellness marketing. The underlying biology is real; the way it is usually presented is not particularly useful.

The ratio matters because EPA and AA compete for the same membrane positions and the same enzymes. So the ratio of EPA to AA in your membranes – which reflects your dietary pattern over time – directly shapes your eicosanoid balance. The modern Western diet provides an omega-6 to omega-3 ratio of roughly 15–20:1, compared to an estimated evolutionary ratio of around 4:1, driven by the widespread use of seed oils and relatively low oily fish intake. ^[1]

But here is what the ratio framing misses: it is a proxy for what actually matters, which is the absolute EPA and AA content of your cell membranes. Obsessing over a target ratio without knowing your baseline is less useful than simply ensuring adequate EPA and DHA intake – around 1–2 g daily from food or supplements – alongside a reasonable reduction in the high-omega-6 seed oils that dominate processed food. The ratio improves as a consequence of doing both sensibly, not as something to track directly.

Omega-3, Barrier Function, and the Evidence in Skin Conditions

Essential fatty acid deficiency – encompassing omega-3 and omega-6 – produces a recognisable skin syndrome: dry, scaly skin, increased TEWL, impaired barrier recovery, and heightened vulnerability to irritant and allergic reactions. Omega-3 fatty acids contribute to the structural phospholipid composition of keratinocyte membranes and to the free fatty acid content of the stratum corneum lipid matrix alongside ceramides and cholesterol. The skin cannot make EPA or DHA. It relies entirely on what the diet provides. ^[5]

The causal relationship between omega-3 status and atopic dermatitis risk was confirmed by a 2023 Mendelian randomisation study; a design that uses genetic variants to establish causality rather than association, which is a methodologically stronger foundation than observational cohort data. Higher genetically predicted n-3 fatty acid levels were causally associated with reduced AD risk, operating through the FADS gene cluster governing the rate-limiting desaturation steps in PUFA synthesis. This shifts the omega-3/AD relationship from “associated with” to “causal.” That is a meaningful distinction. ^[5]

The clinical supplementation evidence across skin conditions is honest and mixed:

• Psoriasis: the strongest evidence base of any skin condition. Multiple trials show improvements in PASI scores, pruritus, and erythema. The mechanism is well-supported: AA-derived PGE₂ drives the keratinocyte hyperproliferation that characterises psoriatic plaques, and EPA’s competitive displacement directly addresses this
• Atopic dermatitis: significant SCORAD improvements in RCTs, with the Mendelian randomisation evidence adding causal weight. A paediatric RCT combining omega-3 with GLA and vitamin D showed significant severity reduction ^[6]
• Acne: mechanistic basis exists through PGE₂/LTB₄ reduction in the pilosebaceous unit, but clinical evidence is limited and sample sizes small
• Rosacea: one placebo-controlled study showed benefit for ocular rosacea dry eye; cutaneous evidence is limited